SCHEMBL2907501

SCHEMBL2907501

Cc1ccc(C(=O)O)cc1-c1ccc(NC(=O)c2cccc(Br)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 2/20 0.55
NR1H4 Q96RI1 1/20 0.54
MAPK14 Q16539 6/20 0.53
TP53 P04637 1/20 0.51
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
HPSE Q9Y251 1/20 0.49
GFER P55789 1/20 0.48
PLAU P00749 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906890 0.84 MAPK14 (0.65) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL2344382 0.82 MAPK14 (0.61) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL2914486 0.80 KMT2A (0.57) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL4762822 0.80 IL2 (0.60) KMT2AMEN1NR1H4MAPK14
SCHEMBL12189683 0.79 PTPN1 (0.67) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL2914737 0.79 PKM (0.61) SMN1; SMN2NPC1RAB9ACASP3SENP7
SCHEMBL17664561 0.78 RAB9A (0.71) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL2914522 0.77 LMNA (0.57) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL13198154 0.77 MAPK14 (0.61) KMT2AMEN1NR1H4MAPK14TP53
SCHEMBL12189596 0.76 KMT2A (0.70) SMN1; SMN2NPC1RAB9ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 SMN1; SMN2 2314/4885NPC1 146/4885RAB9A 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.